识别和监测儿童及青少年使用第二代抗精神病药物的不良事件。

Recognizing and monitoring adverse events of second-generation antipsychotics in children and adolescents.

作者信息

Correll Christoph U, Penzner Julie B, Parikh Umesh H, Mughal Tahir, Javed Tariq, Carbon Maren, Malhotra Anil K

机构信息

The Zucker Hillside Hospital, North Shore-Long Island Jewish Health System, 75-59 263rd Street, Glen Oaks, NY 11004, USA.

出版信息

Child Adolesc Psychiatr Clin N Am. 2006 Jan;15(1):177-206. doi: 10.1016/j.chc.2005.08.007.

DOI:10.1016/j.chc.2005.08.007

PMID:16321730

Abstract

Although second-generation antipsychotics (SGAs) are used increasingly in children and adolescents, data on the effectiveness and safety in pediatric populations are still sparse. Much of the safety information is derived from studies conducted in adults. This derivation is problematic because children and adolescents are exposed to SGAs during a phase of unparalleled physical and psychologic development that can affect pharmacokinetic and pharmacodynamic drug actions, efficacy, and side-effect patterns. This article presents an overview of SGA-related side effects in children and adolescents and strategies to monitor health outcomes effectively in youngsters receiving SGAs.

摘要

尽管第二代抗精神病药物（SGA）在儿童和青少年中的使用越来越多，但关于儿科人群有效性和安全性的数据仍然稀少。许多安全信息来自于在成人中进行的研究。这种推导存在问题，因为儿童和青少年在一个身体和心理发育无与伦比的阶段接触SGA，这可能会影响药物的药代动力学和药效学作用、疗效及副作用模式。本文概述了儿童和青少年中与SGA相关的副作用，以及在接受SGA治疗的青少年中有效监测健康结果的策略。